WCLC 2023 | Continuing IO in geriatric patients with NSCLC with radiographic progression

Eric Singhi, MD, The University of Texas MD Anderson Cancer Centre, Houston, TX, shares the result of an analysis of older adult patients (70 years old and over) with non-small cell lung cancer (NSCLC) who continued immunotherapy (IO) beyond documented radiographic progression. The analysis demonstrated that there was clinical benefit in a select group of patients who continued the treatment. Dr Singhi emphasises that biomarkers, patient characteristics and disease characteristics must be identified to understand which patient sub-population may benefit from this treatment strategy. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.